Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | GPR27 | Q9NS67 | 3/20 | 0.51 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CPT1A | P50416 | 1/20 | 0.46 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.45 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2828290 | 0.94 | GPR27 (0.52) | LMNASMN1; SMN2GPR27AVPR2MEN1 | |
| SCHEMBL2828110 | 0.90 | LMNA (0.53) | LMNASMN1; SMN2GPR27AVPR2MEN1 | |
| SCHEMBL2824639 | 0.88 | GPR27 (0.57) | GPR27AVPR2MEN1KMT2ANPC1 | |
| SCHEMBL2826890 | 0.86 | SMN1; SMN2 (0.64) | LMNASMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL2827058 | 0.84 | MEN1 (0.55) | LMNASMN1; SMN2GPR27AVPR2MEN1 | |
| SCHEMBL2825255 | 0.81 | AVPR2 (0.59) | LMNAGPR27AVPR2MEN1KMT2A | |
| SCHEMBL28869954 | 0.80 | LMNA (0.72) | LMNASMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL2828894 | 0.79 | SMN1; SMN2 (0.63) | LMNASMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL2831130 | 0.78 | MAPT (0.50) | LMNASMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL2828881 | 0.78 | CPT1A (0.65) | LMNASMN1; SMN2MAPTHTTCPT1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232104-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | BLEICHER KONRAD (DE) | 2012-09-13 | — | — | US | disclosed |
| US-20110319438-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | BLEICHER KONRAD (DE) | 2011-12-29 | — | — | US | disclosed |
| US-20100144762-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | BLEICHER KONRAD | 2010-06-10 | — | — | US | disclosed |
| US-7723538-B2 | enzyme inhibitors of membrane-bound carnitine-dependent palmitoyltransferases (CPTs); inhibit gluconeogenesis and therefore counteract hyperglycemia; 4-(3-Benzenesulfonylamino-benzoylamino)-benzoic acid | HOFFMANN-LA ROCHE INC. (US) | 2010-05-25 | — | — | US | disclosed |
| EP-1891001-B1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | disclosed |
| EP-1891001-A1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | F. Hoffmann-Roche AG (CH) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006131452-A1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-14 | — | — | WO | disclosed |
| US-20060276494-A1 | Novel sulfonamides as L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276494-A1 | Novel sulfonamides as L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | LMNA 3524/4885SMN1; SMN2 2229/4885GPR27 2547/4885 |
| US-20120232104-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | LMNA 3524/4885SMN1; SMN2 2229/4885GPR27 2547/4885 |
| US-20100144762-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | LMNA 3524/4885SMN1; SMN2 2229/4885GPR27 2547/4885 |
| US-20110319438-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | LMNA 3524/4885SMN1; SMN2 2229/4885GPR27 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.